Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Longvida Curcumin in Dry AMD
NCT04590196Phase 1Completed
- Sponsor
- University of Illinois Chicago
- Start
- Nov 2020
- Primary completion
- Jun 2023
- Modality
- Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in age-related macular degeneration (AMD) comparing Longvida Curcumin with Placebo (2 arms). Primary endpoint: Drusen volume at 12 months. Started Nov 2020; status: completed.
02
Drugs
Longvida
03
Conditions
age-related macular degeneration (AMD)
Beyond the preview
Go deeper on NCT04590196.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04590196.